Efficacy and Tolerability of Telmisartan Plus Amlodipine in Asian Patients Not Adequately Controlled on Either Monotherapy or on Low-Dose Combination Therapy

Objective. To evaluate the efficacy and safety of the telmisartan plus amlodipine (T/A) single-pill combination (SPC) in Asian patients with hypertension whose blood pressure (BP) was not adequately controlled on either monotherapy or on low-dose combination therapy. Patients and Methods. Data are p...

Full description

Saved in:
Bibliographic Details
Main Authors: Dingliang Zhu, Pingjin Gao, Nobutaka Yagi, Helmut Schumacher
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:International Journal of Hypertension
Online Access:http://dx.doi.org/10.1155/2014/475480
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850175000100732928
author Dingliang Zhu
Pingjin Gao
Nobutaka Yagi
Helmut Schumacher
author_facet Dingliang Zhu
Pingjin Gao
Nobutaka Yagi
Helmut Schumacher
author_sort Dingliang Zhu
collection DOAJ
description Objective. To evaluate the efficacy and safety of the telmisartan plus amlodipine (T/A) single-pill combination (SPC) in Asian patients with hypertension whose blood pressure (BP) was not adequately controlled on either monotherapy or on low-dose combination therapy. Patients and Methods. Data are presented from five Boehringer Ingelheim-sponsored phase 3, double-blind, 8-week, studies: two studies in nonresponders to amlodipine (data pooled for amlodipine), two studies on nonresponders to telmisartan (pooled data), and one on nonresponders to low-dose T/A SPC. Results. After 8 weeks’ treatment, mean reductions from the reference baseline in diastolic BP (DBP; primary endpoint), systolic BP (SBP), and SBP, DBP goal, and response rates were higher with the T/A SPC than respective monotherapies. The T80/A5 SPC resulted in greater reductions in DBP and SBP, and higher DBP goal and response rate than the low-dose T40/A5 SPC. Peripheral edema incidence was low (amlodipine 0.5%, telmisartan 0.0%, and T/A SPC 0.7%). Discussion and Conclusion. In Asian patients whose BP is not adequately controlled with telmisartan or amlodipine monotherapy, T/A SPC treatment results in greater BP reduction, and higher DBP and SBP goal and response rates. The safety and tolerability of the T/A SPC are comparable to those of the respective monotherapies and consistent with those reported in previous studies.
format Article
id doaj-art-d741390d8da74a1a853f58c1a8b2fbf6
institution OA Journals
issn 2090-0384
2090-0392
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series International Journal of Hypertension
spelling doaj-art-d741390d8da74a1a853f58c1a8b2fbf62025-08-20T02:19:33ZengWileyInternational Journal of Hypertension2090-03842090-03922014-01-01201410.1155/2014/475480475480Efficacy and Tolerability of Telmisartan Plus Amlodipine in Asian Patients Not Adequately Controlled on Either Monotherapy or on Low-Dose Combination TherapyDingliang Zhu0Pingjin Gao1Nobutaka Yagi2Helmut Schumacher3Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hypertension, 197 Ruijin Road, Shanghai 200025, ChinaRuijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hypertension, 197 Ruijin Road, Shanghai 200025, ChinaNippon Boehringer Ingelheim Co., Ltd , 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017, JapanBoehringer Ingelheim Pharma GmbH & Co. KG, Binger Straße 173, 55216 Ingelheim, GermanyObjective. To evaluate the efficacy and safety of the telmisartan plus amlodipine (T/A) single-pill combination (SPC) in Asian patients with hypertension whose blood pressure (BP) was not adequately controlled on either monotherapy or on low-dose combination therapy. Patients and Methods. Data are presented from five Boehringer Ingelheim-sponsored phase 3, double-blind, 8-week, studies: two studies in nonresponders to amlodipine (data pooled for amlodipine), two studies on nonresponders to telmisartan (pooled data), and one on nonresponders to low-dose T/A SPC. Results. After 8 weeks’ treatment, mean reductions from the reference baseline in diastolic BP (DBP; primary endpoint), systolic BP (SBP), and SBP, DBP goal, and response rates were higher with the T/A SPC than respective monotherapies. The T80/A5 SPC resulted in greater reductions in DBP and SBP, and higher DBP goal and response rate than the low-dose T40/A5 SPC. Peripheral edema incidence was low (amlodipine 0.5%, telmisartan 0.0%, and T/A SPC 0.7%). Discussion and Conclusion. In Asian patients whose BP is not adequately controlled with telmisartan or amlodipine monotherapy, T/A SPC treatment results in greater BP reduction, and higher DBP and SBP goal and response rates. The safety and tolerability of the T/A SPC are comparable to those of the respective monotherapies and consistent with those reported in previous studies.http://dx.doi.org/10.1155/2014/475480
spellingShingle Dingliang Zhu
Pingjin Gao
Nobutaka Yagi
Helmut Schumacher
Efficacy and Tolerability of Telmisartan Plus Amlodipine in Asian Patients Not Adequately Controlled on Either Monotherapy or on Low-Dose Combination Therapy
International Journal of Hypertension
title Efficacy and Tolerability of Telmisartan Plus Amlodipine in Asian Patients Not Adequately Controlled on Either Monotherapy or on Low-Dose Combination Therapy
title_full Efficacy and Tolerability of Telmisartan Plus Amlodipine in Asian Patients Not Adequately Controlled on Either Monotherapy or on Low-Dose Combination Therapy
title_fullStr Efficacy and Tolerability of Telmisartan Plus Amlodipine in Asian Patients Not Adequately Controlled on Either Monotherapy or on Low-Dose Combination Therapy
title_full_unstemmed Efficacy and Tolerability of Telmisartan Plus Amlodipine in Asian Patients Not Adequately Controlled on Either Monotherapy or on Low-Dose Combination Therapy
title_short Efficacy and Tolerability of Telmisartan Plus Amlodipine in Asian Patients Not Adequately Controlled on Either Monotherapy or on Low-Dose Combination Therapy
title_sort efficacy and tolerability of telmisartan plus amlodipine in asian patients not adequately controlled on either monotherapy or on low dose combination therapy
url http://dx.doi.org/10.1155/2014/475480
work_keys_str_mv AT dingliangzhu efficacyandtolerabilityoftelmisartanplusamlodipineinasianpatientsnotadequatelycontrolledoneithermonotherapyoronlowdosecombinationtherapy
AT pingjingao efficacyandtolerabilityoftelmisartanplusamlodipineinasianpatientsnotadequatelycontrolledoneithermonotherapyoronlowdosecombinationtherapy
AT nobutakayagi efficacyandtolerabilityoftelmisartanplusamlodipineinasianpatientsnotadequatelycontrolledoneithermonotherapyoronlowdosecombinationtherapy
AT helmutschumacher efficacyandtolerabilityoftelmisartanplusamlodipineinasianpatientsnotadequatelycontrolledoneithermonotherapyoronlowdosecombinationtherapy